Serum matrix metalloproteinase‐7, Syndecan‐1, and CA 19‐9 as a biomarker panel for diagnosis of pancreatic ductal adenocarcinoma
Abstract Aims and Background Matrix metalloproteinase‐7 (MMP‐7) and Syndecan‐1 (SDC1) are involved in multiple functions during tumorigenesis. We aimed to evaluate the diagnostic and prognostic performance of these serum proteins, as potential biomarkers, in patients with pancreatic ductal adenocarc...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-09-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70144 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206469688033280 |
|---|---|
| author | Doron Yablecovitch Moshe Nadler Shomron Ben‐Horin Orit Picard Miri Yavzori Ella Fudim Moran Tardio Duchan Emad Sakhnini Alon Lang Maor Lahav Talia Saker Sandra Neuman Limor Selinger Biana Freitz Revital Dvir Maria Raitses‐Gurevich Talia Golan Idan Levy Ido Laish |
| author_facet | Doron Yablecovitch Moshe Nadler Shomron Ben‐Horin Orit Picard Miri Yavzori Ella Fudim Moran Tardio Duchan Emad Sakhnini Alon Lang Maor Lahav Talia Saker Sandra Neuman Limor Selinger Biana Freitz Revital Dvir Maria Raitses‐Gurevich Talia Golan Idan Levy Ido Laish |
| author_sort | Doron Yablecovitch |
| collection | DOAJ |
| description | Abstract Aims and Background Matrix metalloproteinase‐7 (MMP‐7) and Syndecan‐1 (SDC1) are involved in multiple functions during tumorigenesis. We aimed to evaluate the diagnostic and prognostic performance of these serum proteins, as potential biomarkers, in patients with pancreatic ductal adenocarcinoma (PDAC) and benign pancreatic cysts. Methods In this case–control study, patients with newly diagnosed PDAC (N = 121) were compared with the benign cyst (N = 66) and healthy control (N = 48) groups. Serum MMP‐7 and SDC1 were measured by ELISA. The diagnostic accuracy of their levels for diagnosing PDAC and pancreatic cysts was computed, and their association with survival outcomes was evaluated. Results MMP‐7 median serum levels were significantly elevated in the PDAC (7.3 ng/mL) and cyst groups (3.7 ng/mL) compared with controls (2.9 ng/mL) (p < 0.001 and 0.02, respectively), and also between the PDAC and cyst groups (p < 0.001), while SDC1 median serum levels were significantly elevated in PDAC (43.3 ng/mL) compared with either cysts (30.1 ng/mL, p < 0.001) or controls (31.2 ng/mL, p < 0.001). The receiver operating characteristic curve analysis area under the curve in PDAC versus controls was 0.90 and 0.78 for MMP‐7 and SDC1, respectively, while it was 1.0 for the combination of the two and CA 19‐9 (p < 0.001). The combination of the three biomarkers had a perfect sensitivity (100%). Conclusions Due to its high sensitivity, this biomarker panel has the potential to rule out PDAC in suspected cases. |
| format | Article |
| id | doaj-art-3aac0182b66c4954996c3396737ad366 |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-3aac0182b66c4954996c3396737ad3662025-02-07T09:08:08ZengWileyCancer Medicine2045-76342024-09-011317n/an/a10.1002/cam4.70144Serum matrix metalloproteinase‐7, Syndecan‐1, and CA 19‐9 as a biomarker panel for diagnosis of pancreatic ductal adenocarcinomaDoron Yablecovitch0Moshe Nadler1Shomron Ben‐Horin2Orit Picard3Miri Yavzori4Ella Fudim5Moran Tardio Duchan6Emad Sakhnini7Alon Lang8Maor Lahav9Talia Saker10Sandra Neuman11Limor Selinger12Biana Freitz13Revital Dvir14Maria Raitses‐Gurevich15Talia Golan16Idan Levy17Ido Laish18Gastroenterology Institute Chaim Sheba Medical Center Tel Hashomer IsraelGastroenterology Institute Chaim Sheba Medical Center Tel Hashomer IsraelGastroenterology Institute Chaim Sheba Medical Center Tel Hashomer IsraelGastroenterology Institute Chaim Sheba Medical Center Tel Hashomer IsraelGastroenterology Institute Chaim Sheba Medical Center Tel Hashomer IsraelGastroenterology Institute Chaim Sheba Medical Center Tel Hashomer IsraelGastroenterology Institute Chaim Sheba Medical Center Tel Hashomer IsraelGastroenterology Institute Chaim Sheba Medical Center Tel Hashomer IsraelGastroenterology Institute Chaim Sheba Medical Center Tel Hashomer IsraelGastroenterology Institute Chaim Sheba Medical Center Tel Hashomer IsraelSackler School of Medicine Tel Aviv University Tel Aviv IsraelGastroenterology Institute Chaim Sheba Medical Center Tel Hashomer IsraelGastroenterology Institute Chaim Sheba Medical Center Tel Hashomer IsraelGastroenterology Institute Chaim Sheba Medical Center Tel Hashomer IsraelGastroenterology Institute Chaim Sheba Medical Center Tel Hashomer IsraelSackler School of Medicine Tel Aviv University Tel Aviv IsraelSackler School of Medicine Tel Aviv University Tel Aviv IsraelGastroenterology Institute Chaim Sheba Medical Center Tel Hashomer IsraelGastroenterology Institute Chaim Sheba Medical Center Tel Hashomer IsraelAbstract Aims and Background Matrix metalloproteinase‐7 (MMP‐7) and Syndecan‐1 (SDC1) are involved in multiple functions during tumorigenesis. We aimed to evaluate the diagnostic and prognostic performance of these serum proteins, as potential biomarkers, in patients with pancreatic ductal adenocarcinoma (PDAC) and benign pancreatic cysts. Methods In this case–control study, patients with newly diagnosed PDAC (N = 121) were compared with the benign cyst (N = 66) and healthy control (N = 48) groups. Serum MMP‐7 and SDC1 were measured by ELISA. The diagnostic accuracy of their levels for diagnosing PDAC and pancreatic cysts was computed, and their association with survival outcomes was evaluated. Results MMP‐7 median serum levels were significantly elevated in the PDAC (7.3 ng/mL) and cyst groups (3.7 ng/mL) compared with controls (2.9 ng/mL) (p < 0.001 and 0.02, respectively), and also between the PDAC and cyst groups (p < 0.001), while SDC1 median serum levels were significantly elevated in PDAC (43.3 ng/mL) compared with either cysts (30.1 ng/mL, p < 0.001) or controls (31.2 ng/mL, p < 0.001). The receiver operating characteristic curve analysis area under the curve in PDAC versus controls was 0.90 and 0.78 for MMP‐7 and SDC1, respectively, while it was 1.0 for the combination of the two and CA 19‐9 (p < 0.001). The combination of the three biomarkers had a perfect sensitivity (100%). Conclusions Due to its high sensitivity, this biomarker panel has the potential to rule out PDAC in suspected cases.https://doi.org/10.1002/cam4.70144biomarkersmatrix metalloproteinase‐7pancreatic cancerSyndecan‐1 |
| spellingShingle | Doron Yablecovitch Moshe Nadler Shomron Ben‐Horin Orit Picard Miri Yavzori Ella Fudim Moran Tardio Duchan Emad Sakhnini Alon Lang Maor Lahav Talia Saker Sandra Neuman Limor Selinger Biana Freitz Revital Dvir Maria Raitses‐Gurevich Talia Golan Idan Levy Ido Laish Serum matrix metalloproteinase‐7, Syndecan‐1, and CA 19‐9 as a biomarker panel for diagnosis of pancreatic ductal adenocarcinoma Cancer Medicine biomarkers matrix metalloproteinase‐7 pancreatic cancer Syndecan‐1 |
| title | Serum matrix metalloproteinase‐7, Syndecan‐1, and CA 19‐9 as a biomarker panel for diagnosis of pancreatic ductal adenocarcinoma |
| title_full | Serum matrix metalloproteinase‐7, Syndecan‐1, and CA 19‐9 as a biomarker panel for diagnosis of pancreatic ductal adenocarcinoma |
| title_fullStr | Serum matrix metalloproteinase‐7, Syndecan‐1, and CA 19‐9 as a biomarker panel for diagnosis of pancreatic ductal adenocarcinoma |
| title_full_unstemmed | Serum matrix metalloproteinase‐7, Syndecan‐1, and CA 19‐9 as a biomarker panel for diagnosis of pancreatic ductal adenocarcinoma |
| title_short | Serum matrix metalloproteinase‐7, Syndecan‐1, and CA 19‐9 as a biomarker panel for diagnosis of pancreatic ductal adenocarcinoma |
| title_sort | serum matrix metalloproteinase 7 syndecan 1 and ca 19 9 as a biomarker panel for diagnosis of pancreatic ductal adenocarcinoma |
| topic | biomarkers matrix metalloproteinase‐7 pancreatic cancer Syndecan‐1 |
| url | https://doi.org/10.1002/cam4.70144 |
| work_keys_str_mv | AT doronyablecovitch serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma AT moshenadler serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma AT shomronbenhorin serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma AT oritpicard serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma AT miriyavzori serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma AT ellafudim serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma AT morantardioduchan serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma AT emadsakhnini serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma AT alonlang serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma AT maorlahav serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma AT taliasaker serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma AT sandraneuman serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma AT limorselinger serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma AT bianafreitz serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma AT revitaldvir serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma AT mariaraitsesgurevich serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma AT taliagolan serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma AT idanlevy serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma AT idolaish serummatrixmetalloproteinase7syndecan1andca199asabiomarkerpanelfordiagnosisofpancreaticductaladenocarcinoma |